Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Mirum Pharmaceuticals ( (MIRM) ) is now available.
On January 23, 2026, Mirum Pharmaceuticals completed its acquisition of privately held Bluejay Therapeutics, folding the biotech into a wholly owned subsidiary structure and adding approximately $56.6 million in net cash alongside worldwide rights to brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus (HDV), in a deal structured as cash, Mirum stock and potential tiered sales-based milestone payments to Bluejay security holders, including affiliates of Frazier Life Sciences IX. The transaction, announced publicly on January 26, 2026, expands Mirum’s rare liver disease franchise with a Breakthrough Therapy- and PRIME-designated asset now in the global AZURE Phase 3 registrational program, while concurrent private placement financings with existing and new healthcare investors raised about $268.5 million, bolstering Mirum’s balance sheet to fund development and commercialization plans and leaving the company with 59,879,958 common shares outstanding, a move that reinforces its positioning as a leading player in rare liver conditions and could be consequential for HDV patients who currently lack approved therapies in major markets.
The most recent analyst rating on (MIRM) stock is a Buy with a $130.00 price target. To see the full list of analyst forecasts on Mirum Pharmaceuticals stock, see the MIRM Stock Forecast page.
Spark’s Take on MIRM Stock
According to Spark, TipRanks’ AI Analyst, MIRM is a Neutral.
The score is held back primarily by weak underlying profitability and elevated leverage (financial performance), plus limited support from traditional valuation metrics given the negative P/E. Offsetting these are strong technical momentum and a positive earnings-call profile with raised guidance, improving commercialization, and meaningful upcoming pipeline catalysts.
To see Spark’s full report on MIRM stock, click here.
More about Mirum Pharmaceuticals
Mirum Pharmaceuticals (NASDAQ: MIRM) is a rare disease-focused biopharmaceutical company with a global commercial footprint built around treatments for underserved liver and metabolic disorders. Its approved portfolio includes LIVMARLI for Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM for bile acid synthesis disorders, and CTEXLI for cerebrotendinous xanthomatosis, complemented by a clinical pipeline that spans late-stage candidates for primary sclerosing cholangitis, primary biliary cholangitis, chronic hepatitis delta virus and Fragile X syndrome.
Average Trading Volume: 735,600
Technical Sentiment Signal: Buy
Current Market Cap: $4.87B
For detailed information about MIRM stock, go to TipRanks’ Stock Analysis page.